Floatz logo

Linperlisib

Extranodal Natural Killer/T Cell Lymphoma

Sun Yat-sen UniversitySmall moleculePhase 1/2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Extranodal Natural Killer/T Cell Lymphoma cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Linperlisib is also rated in:

Indolent B-cell LymphomaDormant
BB
Indicative ·
65 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
B
Indicative ·
61 / 100
View asset →
relapsed/refractory diffuse large B-cell lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →